| Acute bacterial skin and skin structure infection

Teflaro vs Kimyrsa

Side-by-side clinical, coverage, and cost comparison for acute bacterial skin and skin structure infection.

Deep comparison between: Teflaro vs Kimyrsa with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKimyrsa has a higher rate of injection site reactions vs Teflaro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Kimyrsa but not Teflaro, including UnitedHealthcare

Category

Teflaro

Kimyrsa

At A Glance

RouteIV infusion

FrequencyEvery 12 hours

ClassCephalosporin antibacterial

RouteIV infusion

FrequencySingle dose

ClassLipoglycopeptide antibacterial

Indications

Acute bacterial skin and skin structure infection
Community-Acquired Pneumonia

Acute bacterial skin and skin structure infection

Dosing

Acute bacterial skin and skin structure infection Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-14 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours; neonates (gestational age >=34 weeks, postnatal age >=12 days) to <2 months: 6 mg/kg every 8 hours over 30 to 60 minutes.

Community-Acquired Pneumonia Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-7 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours over 5 to 60 minutes for 5-14 days.

Acute bacterial skin and skin structure infection 1,200 mg as a single dose by intravenous infusion over 1 hour in patients 18 years and older.

Contraindications

Known serious hypersensitivity to ceftaroline or other members of the cephalosporin class

Use of intravenous unfractionated heparin sodium for 120 hours (5 days) after KIMYRSA administration due to false aPTT elevation
Known hypersensitivity to oritavancin products

Drug Interactions

1068View drug interactions

971View drug interactions

Adverse Reactions

Most common (>=2%) Diarrhea, nausea, rash, constipation, vomiting, increased transaminases, hypokalemia, phlebitis

Serious Hypersensitivity reactions, anaphylaxis, Clostridioides difficile-associated diarrhea, neurological adverse reactions (dizziness, convulsion), direct Coombs' test seroconversion

Postmarketing Agranulocytosis, leukopenia, eosinophilic pneumonia, encephalopathy, seizures

Most common (>=3%) Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea

Serious Cellulitis, osteomyelitis, hypersensitivity reactions, infusion related reactions, Clostridioides difficile-associated diarrhea

Pharmacology

Ceftaroline is a cephalosporin antibacterial that exerts bactericidal activity by binding to essential penicillin-binding proteins (PBPs), including PBP2a in S. aureus and PBP2x in S. pneumoniae, and has in vitro activity against both Gram-positive and Gram-negative bacteria.

Oritavancin is a semisynthetic lipoglycopeptide antibacterial that exerts concentration-dependent bactericidal activity via three mechanisms: inhibition of cell wall transglycosylation and transpeptidation steps, and disruption of bacterial membrane integrity, active against Gram-positive organisms including methicillin-resistant S. aureus.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Teflaro